QLTI Share Price

Open 1.82 Change Price %
High 2.22 1 Day 0.12 6.56
Low 1.81 1 Week 0.00 0.00
Close 1.95 1 Month 0.21 12.07
Volume 812517 1 Year -0.84 -30.11
52 Week High 2.78
52 Week Low 1.22
QLTI Important Levels
Resistance 2 2.33
Resistance 1 2.17
Pivot 1.99
Support 1 1.73
Support 2 1.57
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

QLT Inc. (NASDAQ: QLTI)

QLTI Technical Analysis 3
As on 29th Nov 2016 QLTI Share Price closed @ 1.95 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.82 & Buy for SHORT-TERM with Stoploss of 1.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
QLTI Target for December
1st Target up-side 2.33
2nd Target up-side 2.59
3rd Target up-side 2.85
1st Target down-side 1.57
2nd Target down-side 1.31
3rd Target down-side 1.05
QLTI Other Details
Segment EQ
Market Capital 391665312.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.qltinc.com
QLTI Address
QLTI
887 Great Northern Way
Suite 101
Vancouver, BC V5T 4T5
Canada
Phone: 604-707-7000
Fax: 604-707-7001
QLTI Latest News
Interactive Technical Analysis Chart QLT Inc. ( QLTI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on QLT Inc.
QLTI Business Profile
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. It develops QLT091001, a synthetic retinoid compound for the potential treatment of certain inherited retinal degenerative diseases. In September 2012,it sold all of its assets related to Visudyne to Valeant Pharmaceuticals International, Inc. (Valeant). It also sold Qcellus laser and certain other photodynamic therapy intellectual property, In April 2013, it sold its punctal plug drug delivery system (PPDS) technology (Technology) to Mati Therapeutics Inc. (Mati). It is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. It is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).